Recent Updates
Recently added Catalysts

NIR

Phase 1

Pancreatic Neuroendocrine Tumors | Unknown | Oncology |Verona Pharma plc Sponsored ADR|Last Updated: Mar 7, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment10
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02685553Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN ProjectPHASE1 COMPLETED 10Feb 1, 2016Oct 1, 2016Mar 7, 20171 Italy
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of hypervascular pancreatic neoplasms detected intraoperatively by NIR
within the time of surgery
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
1EXPERIMENTALUse of NIR
Interventions
NameTypeDescription
NIRDEVICELaparoscopic use of NIR
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * age between 18 and 80 * diagnosis of hypervascular pancreatic neoplasms to be treated with laparoscopic surgery Exclusion Criteria: * allergy to indocyanine green or other vital stains, indium, shellfish * chronic kidney insufficiency * chronic hepatopathy * hyperthyroidism,...

Countries:Italy
Unlock Eligibility Criteria